HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Inclusion Criteria: * Subjects must have metastatic or unresectable locally advanced malignant solid tumor. * Patients may have measurable or non-measurable but evaluable disease. * Patients with surgically resected metastatic disease at high risk of relapse are also eligible. * Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease, or not be candidates for therapy of proven efficacy for their disease. * Patients must have recovered (grade 1 or baseline) from any clinically significant toxicity associated with prior therapy * Age ≥ 18 years. . * ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1 (Karnofsky ≥ 70%). * Patients must have normal organ and hematologic function therapy * Patients must have baseline pulse oximetry \> 90% on room air Exclusion Criteria: * Pregnant women or women presently breast-feeding * Concurrent treatment for cancer * Chronic hepatitis B or C infection. * Any significant disease that, in the opinion of the investigator, may impair the patient's tolerance of study treatment. * Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. * Active autoimmune diseases requiring treatment or a history of autoimmune disease. * Concurrent use of systemic steroids * Patients who are receiving any other investigational agents * Patients with untreated central nervous system metastases or local treatment of brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agent used in study. * Serious or uncontrolled intercurrent illness * HIV-positive patients are ineligible * Patients unwilling to use adequate contraception Other protocol defined inclusion/exclusion criteria could apply